[
    "{\"step_by_step_thinking\": \"Sacituzumab govitecan is an antibody-drug conjugate that targets Trop-2 expressing cells and selectively delivers SN-38, an active metabolite of irinotecan. According to the documents, it has shown promising anti-cancer activity in patients with metastatic triple-negative breast cancer (TNBC) previously treated with at least two prior lines of systemic therapy. It has been granted breakthrough therapy designation by the Food and Drug Administration as a third-line therapy for metastatic TNBC. In a phase III clinical trial, sacituzumab govitecan demonstrated a median progression-free survival of 5.7 months vs. 1.7 months with chemotherapy. Therefore, it can be concluded that sacituzumab govitecan is effective for breast cancer.\", \"answer_choice\": \"A\"}"
]